CTVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Corteva Inc (CTVA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive catalysts, the lack of strong trading signals, mixed analyst ratings, and recent financial performance suggest holding off on a purchase until more clarity emerges around the company's upcoming business split and financial trends.
The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral at 77.544, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is near resistance levels (R1: 78.312, R2: 79.483), which could limit immediate upside potential.
Analysts have raised price targets, with some firms maintaining Outperform or Buy ratings.
The company has resolved litigation with Bayer and is planning a business split, which could unlock value.
Strong global demand for crop protection products.
UBS and JPMorgan have downgraded the stock, citing valuation concerns and execution risks related to the business split.
Revenue declined YoY in Q4 2025, and the company posted a net loss despite improvements in gross margin and EPS.
The agriculture sector faces ongoing price challenges and a choppy global backdrop.
In Q4 2025, revenue dropped by 1.71% YoY to $3.91 billion. However, net income improved significantly to -$552 million (up 1246.34% YoY), and EPS increased to -0.82 (up 1266.67% YoY). Gross margin also improved to 38.29%, up 15.58% YoY. Despite these improvements, the company remains unprofitable, and revenue growth is lacking.
Analyst ratings are mixed. While firms like Goldman Sachs, RBC Capital, and Oppenheimer have raised price targets and remain bullish, UBS and JPMorgan have downgraded the stock due to valuation concerns and risks associated with the upcoming business split.
